Evidence map›Paper›PMID 25393624›Full record

ArticlePloS one2014

Resequencing and association analysis of PTPRA, a possible susceptibility gene for schizophrenia and autism spectrum disorders.

Jingrui Xing, Chenyao Wang, Hiroki Kimura, Yuto Takasaki, Shohko Kunimoto, Akira Yoshimi, Yukako Nakamura, Takayoshi Koide, Masahiro Banno, Itaru Kushima and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Phosphatase Signaling as a Therapeutic Strategy in Schizophrenia.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Jingrui XingDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Chenyao WangDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroki KimuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuto TakasakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shohko KunimotoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Akira YoshimiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yukako NakamuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takayoshi KoideDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masahiro BannoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Itaru KushimaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yota UnoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi OkadaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Branko AleksicDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masashi IkedaDepartment of Psychiatry, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.
Nakao IwataDepartment of Psychiatry, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.
Norio OzakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe PTPRA gene, which encodes the protein RPTP-α, is critical to neurodevelopment. Previous linkage studies, genome-wide association studies, controlled expression analyses and animal models support an association with both schizophrenia and autism spectrum disorders, both of which share a substantial portion of genetic risks.

methodsWe sequenced the protein-encoding areas of the PTPRA gene for single nucleotide polymorphisms or small insertions/deletions (InDel) in 382 schizophrenia patients. To validate their association with the disorders, rare (minor allele frequency <1%), missense mutations as well as one InDel in the 3'UTR region were then genotyped in another independent sample set comprising 944 schizophrenia patients, 336 autism spectrum disorders patients, and 912 healthy controls.

resultsEight rare mutations, including 3 novel variants, were identified during the mutation-screening phase. In the following association analysis, L59P, one of the two missense mutations, was only observed among patients of schizophrenia. Additionally, a novel duplication in the 3'UTR region, 174620_174623dupTGAT, was predicted to be located within a Musashi Binding Element. MAJOR

conclusionsNo evidence was seen for the association of rare, missense mutations in the PTPRA gene with schizophrenia or autism spectrum disorders; however, we did find some rare variants with possibly damaging effects that may increase the susceptibility of carriers to the disorders.

Indexed as

Genetic Predisposition to Disease3' Untranslated RegionsAdolescentAdultAgedCase-Control StudiesChildChild Development Disorders, PervasiveComputational BiologyEvolution, MolecularExonsFemaleGenetic LinkageGenome-Wide Association StudyGenotypeHumans3' Untranslated RegionsPTPRA protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 4

Identifiers

PMID25393624
PMCPMC4231042
OpenAlexW2018368635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.